

- **Full Name:** Lori J. Wirth, MD
 - **Current Position & Affiliation:** The Elizabeth and Michael Ruane Chair of Endocrine Oncology, Medical Director of Head and Neck Oncology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston
 - **Country:** USA
-

• Educational Background:

- Bachelors of Arts, 1987, Brown University, Providence, USA
- Doctor of Medicine, 1997, Columbia College of Physicians and Surgeons, New York City, USA

• Professional Experience:

- Resident in Internal Medicine, 1997-2000, New York Presbyterian Hospital, New York City, USA
- Fellow in Hematology/Oncology, 2000-2003, Dana-Farber/Mass General Hematology/Oncology Fellowship, Harvard Medical School, Boston, USA
- Attending Physician, 2003-2008, Dana-Farber Cancer Institute & Brigham and Women's Hospital, Boston, USA
- Attending Physician, 2008-present, Massachusetts General Hospital, Boston, USA

• Professional Organizations:

- Member, American Society of Clinical Oncology
- Member, American Thyroid Association
- Member & Former Chair, International Thyroid Oncology Group
- Member, American Board of Internal Medicine Oncology Exam Approval Committee
- Member, National Comprehensive Cancer Network Thyroid Cancer Guidelines Committee
- Executive Member, Thyroid International Recommendations Online

• Main Scientific Publications:

1. Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Lebourneux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers, 2020, N Engl J Med, 383(9):825-835.

2. Ho AL, Dedecjus M, Wirth LJ, Tuttle RM, Inabnet III WB, Tennvall J, Vaisman F, Bastholt L, Gianoukakis AG, Rodien P, Paschke R, Elisei R, Viola D, So K, Carroll D, Hovey T, Thakre B, Fagin JA. Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer: a phase 3, randomised, placebo-controlled trial (ASTRA), *J Clin Oncol*, 2022 Feb 22
3. Kiyota N, Tahara M, Robinson B, Schlumberger M, Sherman SI, Leboulleux S, Lee EK, Suzuki T, Ren M, Fushimi K, Wirth LJ. Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial. *Cancer*, 2022 Apr 5
4. Wirth LJ, Durante C, Topliss DJ, Winquist E, Robenshtok E, Iwasaki H, Luster M, Elisei E, Leboulleux S, Tahara M. Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit. *The Oncologist*, 2022 Apr 28
5. Busaidy NL, Konda B, Wei L, Wirth LJ, Devine C, Daniels GA, DeSouza JA, Poi M, Seligson ND, Cabanillas ME, Sipos JA, Ringel MD, Eisfeld AK, Timmers C, Shah MH. Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial. *Thyroid*, 2022 Oct
6. Wirth LJ, Brose MS, Elisei R, Capdevila J, Hoff AO, Hu MI, Tahara M, Robinson B, Gao M, Xia M, Maeda P, Sherman E. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer. *Future Oncol*, 2022 Sep
7. Gild ML, Bullock M, Tsang V, Clifton-Bligh RJ, Robinson BG, Wirth LJ. Challenges and strategies to combat resistance mechanisms in thyroid cancer therapeutics, *Thyroid*, 2023 June 8